Inmode sees FY rev. $365M to $375M, saw $395M to $405M

Inmode sees FY rev. $365M to $375M, saw $395M to $405M

InMode Ltd. (INMD), a leading provider of innovative medical technologies, has revised its full-year 2025 revenue guidance. The company, which delivers radiofrequency-based solutions for minimally invasive aesthetic treatments, expects its full-year revenue to fall between $365 million and $375 million, a decrease from the previously anticipated range of $395 million to $405 million [1].

The adjustment was announced in a public letter by CEO Moshe Mizrahy in response to concerns raised by DOMA Perpetual Capital Management LLC. The company cited market weakness and U.S. economic uncertainty as the primary reasons for the downward revision. Additionally, the company expects its second quarter 2025 revenue to be between $95.4 million and $95.5 million, with a non-GAAP gross margin of 79% to 80% [1].

InMode has also faced criticism regarding its leadership and capital allocation decisions. DOMA Perpetual Capital Management has called for the immediate resumption of the share repurchase program and the removal of CEO Moshe Mizrahy. However, InMode has defended its decisions, noting the company's expertise in manufacturing and its commitment to returning capital to shareholders [2].

The company has participated in several investor conferences and events in recent months, including the BNP 3rd Annual Aesthetics Day, the Barclays West Coast Bus Trip, and the Jefferies Global Healthcare Conference, to update investors on its strategic developments and market leadership [3].

Despite the downward revision in revenue guidance, InMode has secured legal victories against counterfeit sellers of its Morpheus8 radio frequency microneedling devices and needle cartridges. The company has also launched a Verified Provider Program to combat counterfeiting [4].

InMode's stock has been volatile in recent months, with the company facing scrutiny over its financial performance and management decisions. However, the company remains committed to its strategic goals and continues to invest in research and development and acquire patents to enhance its product offerings [5].

References:

[1] https://www.stocktitan.net/news/INMD/
[2] https://www.stocktitan.net/news/INMD/
[3] https://www.stocktitan.net/news/INMD/
[4] https://www.stocktitan.net/news/INMD/
[5] https://www.stocktitan.net/news/INMD/